| __timestamp | Agios Pharmaceuticals, Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 19120000 | 6620800000 |
| Thursday, January 1, 2015 | 35992000 | 6533000000 |
| Friday, January 1, 2016 | 50714000 | 6452000000 |
| Sunday, January 1, 2017 | 71124000 | 6588100000 |
| Monday, January 1, 2018 | 114145000 | 5975100000 |
| Tuesday, January 1, 2019 | 132034000 | 6213800000 |
| Wednesday, January 1, 2020 | 149070000 | 6121200000 |
| Friday, January 1, 2021 | 121445000 | 6431600000 |
| Saturday, January 1, 2022 | 121673000 | 6440400000 |
| Sunday, January 1, 2023 | 119903000 | 6941200000 |
| Monday, January 1, 2024 | 156784000 | 8593800000 |
Unveiling the hidden dimensions of data
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Eli Lilly and Company and Agios Pharmaceuticals, Inc. from 2014 to 2023.
Eli Lilly, a giant in the industry, consistently allocated a significant portion of its budget to SG&A, averaging around $6.4 billion annually. This investment underscores its commitment to maintaining a robust market presence and operational efficiency. In contrast, Agios Pharmaceuticals, a smaller entity, exhibited a more dynamic growth in SG&A expenses, increasing from approximately $19 million in 2014 to $120 million in 2023. This represents a staggering 530% increase, reflecting its aggressive expansion and market penetration strategies.
The data highlights the contrasting financial strategies of these companies, offering insights into their operational priorities and market positioning.
Who Optimizes SG&A Costs Better? Eli Lilly and Company or Zoetis Inc.
Breaking Down SG&A Expenses: Eli Lilly and Company vs Amgen Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs argenx SE Trends and Insights
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Amneal Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Perrigo Company plc
Eli Lilly and Company and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared
Eli Lilly and Company or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Alpine Immune Sciences, Inc. vs Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Agios Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Arrowhead Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.